Several recent Imhotex Ltd. patents describe novel analogues of muramyl dipeptide (MDP), desmuramylpeptides (DMPs), acting as nucleotide-binding oligomerization domain-containing protein 2 (NOD2) activators potentially useful for the treatment of Crohn’s disease.